MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
4.690
+0.320
+7.32%
After Hours: 4.780 +0.09 +1.92% 19:11 11/22 EST
OPEN
4.350
PREV CLOSE
4.370
HIGH
4.700
LOW
4.290
VOLUME
2.33M
TURNOVER
--
52 WEEK HIGH
6.70
52 WEEK LOW
2.280
MARKET CAP
692.15M
P/E (TTM)
-3.5102
1D
5D
1M
3M
1Y
5Y
1D
Balanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External Challenges
TipRanks · 4d ago
Weekly Report: what happened at ADPT last week (1111-1115)?
Weekly Report · 5d ago
Life sciences stocks viewed positively at TD Cowen despite post-election weakness
Seeking Alpha · 11/15 20:55
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
NASDAQ · 11/15 14:55
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations
Simply Wall St · 11/12 18:51
Adaptive Biotechnologies (ADPT) Receives a Buy from Scotiabank
TipRanks · 11/12 12:05
Adaptive Biotechnologies Is Maintained at Overweight by Piper Sandler
Dow Jones · 11/11 13:00
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $7
Benzinga · 11/11 12:49
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.